Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors

Tung Ju Hsieh, Hsien Ya Lin, Zhijay Tu, Ting Chien Lin, Shang Chuen Wu, Yu Yao Tseng, Fu-Tong Liu, Shang Te Danny Hsu, Chun Hung Lin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Human galectins are promising targets for cancer immunotherapeutic and fibrotic disease-related drugs. We report herein the binding interactions of three thio-digalactosides (TDGs) including TDG itself, TD139 (3,3'-deoxy-3,3'-bis-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside, recently approved for the treatment of idiopathic pulmonary fibrosis), and TAZTDG (3-deoxy-3-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside) with human galectins-1,-3 and-7 as assessed by X-ray crystallography, isothermal titration calorimetry and NMR spectroscopy. Five binding subsites (A-E) make up the carbohydrate-recognition domains of these galectins. We identified novel interactions between an arginine within subsite E of the galectins and an arene group in the ligands. In addition to the interactions contributed by the galactosyl sugar residues bound at subsites C and D, the fluorophenyl group of TAZTDG preferentially bound to subsite B in galectin-3, whereas the same group favored binding at subsite E in galectins-1 and-7. The characterised dual binding modes demonstrate how binding potency, reported as decreased Kd values of the TDG inhibitors from μM to nM, is improved and also offer insights to development of selective inhibitors for individual galectins.

Original languageEnglish (US)
Article number29457
JournalScientific Reports
Volume6
DOIs
StatePublished - Jul 15 2016
Externally publishedYes

Fingerprint

Galectins
Galectin 1
Galectin 3
Idiopathic Pulmonary Fibrosis
Calorimetry
X Ray Crystallography
Arginine
Magnetic Resonance Spectroscopy
Carbohydrates
Ligands
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors. / Hsieh, Tung Ju; Lin, Hsien Ya; Tu, Zhijay; Lin, Ting Chien; Wu, Shang Chuen; Tseng, Yu Yao; Liu, Fu-Tong; Hsu, Shang Te Danny; Lin, Chun Hung.

In: Scientific Reports, Vol. 6, 29457, 15.07.2016.

Research output: Contribution to journalArticle

Hsieh, Tung Ju ; Lin, Hsien Ya ; Tu, Zhijay ; Lin, Ting Chien ; Wu, Shang Chuen ; Tseng, Yu Yao ; Liu, Fu-Tong ; Hsu, Shang Te Danny ; Lin, Chun Hung. / Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors. In: Scientific Reports. 2016 ; Vol. 6.
@article{c1eb825af5b44610a4b1c93d676dd4b6,
title = "Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors",
abstract = "Human galectins are promising targets for cancer immunotherapeutic and fibrotic disease-related drugs. We report herein the binding interactions of three thio-digalactosides (TDGs) including TDG itself, TD139 (3,3'-deoxy-3,3'-bis-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside, recently approved for the treatment of idiopathic pulmonary fibrosis), and TAZTDG (3-deoxy-3-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside) with human galectins-1,-3 and-7 as assessed by X-ray crystallography, isothermal titration calorimetry and NMR spectroscopy. Five binding subsites (A-E) make up the carbohydrate-recognition domains of these galectins. We identified novel interactions between an arginine within subsite E of the galectins and an arene group in the ligands. In addition to the interactions contributed by the galactosyl sugar residues bound at subsites C and D, the fluorophenyl group of TAZTDG preferentially bound to subsite B in galectin-3, whereas the same group favored binding at subsite E in galectins-1 and-7. The characterised dual binding modes demonstrate how binding potency, reported as decreased Kd values of the TDG inhibitors from μM to nM, is improved and also offer insights to development of selective inhibitors for individual galectins.",
author = "Hsieh, {Tung Ju} and Lin, {Hsien Ya} and Zhijay Tu and Lin, {Ting Chien} and Wu, {Shang Chuen} and Tseng, {Yu Yao} and Fu-Tong Liu and Hsu, {Shang Te Danny} and Lin, {Chun Hung}",
year = "2016",
month = "7",
day = "15",
doi = "10.1038/srep29457",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors

AU - Hsieh, Tung Ju

AU - Lin, Hsien Ya

AU - Tu, Zhijay

AU - Lin, Ting Chien

AU - Wu, Shang Chuen

AU - Tseng, Yu Yao

AU - Liu, Fu-Tong

AU - Hsu, Shang Te Danny

AU - Lin, Chun Hung

PY - 2016/7/15

Y1 - 2016/7/15

N2 - Human galectins are promising targets for cancer immunotherapeutic and fibrotic disease-related drugs. We report herein the binding interactions of three thio-digalactosides (TDGs) including TDG itself, TD139 (3,3'-deoxy-3,3'-bis-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside, recently approved for the treatment of idiopathic pulmonary fibrosis), and TAZTDG (3-deoxy-3-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside) with human galectins-1,-3 and-7 as assessed by X-ray crystallography, isothermal titration calorimetry and NMR spectroscopy. Five binding subsites (A-E) make up the carbohydrate-recognition domains of these galectins. We identified novel interactions between an arginine within subsite E of the galectins and an arene group in the ligands. In addition to the interactions contributed by the galactosyl sugar residues bound at subsites C and D, the fluorophenyl group of TAZTDG preferentially bound to subsite B in galectin-3, whereas the same group favored binding at subsite E in galectins-1 and-7. The characterised dual binding modes demonstrate how binding potency, reported as decreased Kd values of the TDG inhibitors from μM to nM, is improved and also offer insights to development of selective inhibitors for individual galectins.

AB - Human galectins are promising targets for cancer immunotherapeutic and fibrotic disease-related drugs. We report herein the binding interactions of three thio-digalactosides (TDGs) including TDG itself, TD139 (3,3'-deoxy-3,3'-bis-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside, recently approved for the treatment of idiopathic pulmonary fibrosis), and TAZTDG (3-deoxy-3-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside) with human galectins-1,-3 and-7 as assessed by X-ray crystallography, isothermal titration calorimetry and NMR spectroscopy. Five binding subsites (A-E) make up the carbohydrate-recognition domains of these galectins. We identified novel interactions between an arginine within subsite E of the galectins and an arene group in the ligands. In addition to the interactions contributed by the galactosyl sugar residues bound at subsites C and D, the fluorophenyl group of TAZTDG preferentially bound to subsite B in galectin-3, whereas the same group favored binding at subsite E in galectins-1 and-7. The characterised dual binding modes demonstrate how binding potency, reported as decreased Kd values of the TDG inhibitors from μM to nM, is improved and also offer insights to development of selective inhibitors for individual galectins.

UR - http://www.scopus.com/inward/record.url?scp=84978727256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978727256&partnerID=8YFLogxK

U2 - 10.1038/srep29457

DO - 10.1038/srep29457

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 29457

ER -